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Clinical pharmacists have been incorporating precision medicine into practice for
decades. Drug selection and dosing based on patient-specific clinical factors such as
age, weight, renal function, drug interactions, plasma drug concentrations, and diet
are expected as part of routine clinical practice. Newer concepts of precision medi-
cine such as pharmacogenomics have recently been implemented into clinical care,
while other concepts such as epigenetics and pharmacomicrobiomics still predomi-
nantly exist in the research area but clinical translation is expected in the future. The
purpose of this paper is to describe current and emerging aspects of precision medi-
cine as it relates to clinical pharmacy across a variety of specialty areas of practice,
with perspectives from the American College of Clinical Pharmacy Practice and
Research Network membership.
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1 | INTRODUCTION
The term, “precision medicine” has infiltrated the national dialog about
the future of health care, but misconceptions exist as to the exact
meaning of the phrase. Precision medicine transcends genomics,
incorporating all known data—including variability in genes, environ-
ment, and lifestyle—to target specific treatments and/or disease pre-
vention strategies for each patient.1 The goal is simple: ensure that
each patient is receiving the right drug at the right dose at the right
time. Many terms have been used to describe this concept or varia-
tions of it, including personalized medicine, individualized medicine,
and more recently, precision pharmacotherapy.2 The term precision
medicine may be preferred to personalized or individualized medicine
because the concept does not entail developing drugs and medical
devices unique to every patient. Rather, the concept seeks to classify
individuals into subpopulations that differ in their response to treat-
ment and susceptibility to disease. It is also important to note that
“precision” is being used in a colloquial sense that encompasses both
accuracy and precision, in contrast to the precision (reproducibility) of
a measurement system.
While the term “precision medicine” is relatively new, the con-
cept itself is not new to the pharmacy profession as pharmacists
have been incorporating precision medicine into practice for
decades. Drug selection and dosing based on patient-specific clinical
factors such as age, weight, renal function, drug interactions, plasma
drug concentrations, and diet are expected as part of routine clinical
practice. Aspects of precision medicine, such as pharmacogenomics,
are increasingly applied to patient care, and pharmacists are well-
suited to play a key role in advancing these efforts. The Clinical
Pharmacogenetics Implementation Consortium (CPIC) guidelines pro-
vide clinicians with evidence-based information about how to trans-
late pharmacogenomic data into prescribing decisions. Gene/drug
pairs with published guidelines have a high level of evidence for
implementation (PharmGKB levels 1A/B). Other areas, including
pharmacomicrobiomics, epigenetics, and metabolomics (Table 1), still
predominantly exist in the research sphere but clinical translation is
expected in the future.
The purpose of this paper is to discuss current and emerging
aspects of precision medicine as it relates to clinical pharmacy across
a variety of specialty areas of practice, with perspectives from across
the American College of Clinical Pharmacy (ACCP) Practice and
Research Network (PRN) membership. The writing of this paper was
led by the Pharmacokinetics/Pharmacodynamics/Pharmacogenomics
PRN but represents the opinion of many of the ACCP PRNs (see sec-
tions below). It does not necessarily represent an official ACCP com-
mentary, guideline, or statement of policy or position.
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2 | PERSPECTIVES ON PRECISION
MEDICINE BY PRN
2.1 | Disease-specific specialties
2.1.1 | Cardiology PRN
Within the field of cardiovascular medicine, examples of individualized
therapy include selection of antihypertensive therapy based on the
patient's comorbid conditions (eg, prescribing an angiotensin conver-
ting enzyme inhibitor for nephro-protection in a patient with renal dis-
ease9 and adding hydralazine/isosorbide to heart failure therapy for
patients of African ancestry with continued symptoms10). Data analyt-
ics and advanced statistical techniques have allowed investigators to
determine comorbidities or patient-specific variables that increase the
risk for important clinical events, such as ischemia or bleeding, and
assign a weighted score to each comorbidity/variable. These scoring
systems, such as the Dual Antiplatelet Therapy score or the CathPCI
bleeding risk score, assist the provider in selecting the type and dura-
tion of antiplatelet therapy.11,12 Cardiovascular practitioners also
commonly individualize warfarin based on clinical factors such as age,
weight, diet, and concomitant therapy.13
Genotype provides additional guidance to maximize cardiovascu-
lar drug safety and efficacy. Data are strongest for CYP2C19 and
clopidogrel; CYP2C9 and VKORC1 for warfarin; and SLCO1B1 and sim-
vastatin (Table 2). Pharmacogenomic algorithms are available to calcu-
late warfarin dose requirements based on genotype and clinical
factors (eg, warfarindosing.org). A number of institutions across the
United States have clinically implemented genotyping into practice to
assist with selection of P2Y12 receptor antagonist after percutaneous
coronary intervention, warfarin dosing, and statin prescribing. Data
supporting improved outcomes with genotype-guided approaches are
starting to emerge from pragmatic clinical trials and real-world
studies.14,15
2.1.2 | Central nervous system PRN
Psychiatric clinicians commonly employ patient-specific factors (eg,
demographics, comorbidities, and symptoms), patient preference, and
family history of response to guide medication selection. However,
with the exception of lithium, there are little data to support many of
these strategies.16 In reality, the overarching principle in psychiatry
for medication selection is largely trial-and-error. Other factors
influencing medication response include ensuring the correct diagno-
sis is made, appropriate dose titration, patient acceptance/under-
standing of illness, influence of stigma on taking medications,
TABLE 1 Use of precision medicine in clinical practice
Aspect Definition
Use in clinical
practice Example(s)
Therapeutic drug
monitoring
Measurement of medication concentrations in blood to
improve efficacy, reduce adverse events, or assess
adherence
Common Nortriptyline level
Vancomycin trough
Phenytoin level
PT/INR
Anti-Xa
Aminoglycosides peaks
and troughs
Pharmacogenomics The study of how genes affect an individual's response
to medications (ie, efficacy and/or toxicity) Germline
variant: a DNA alteration (compared with wildtype)
contained within the germline passed from parent to
offspring (Table 2) Somatic variant: an alteration in
DNA that occurs after conception (Table 3)
Occasional (common
in oncology)
CYP450 testing
HLA-B*57:01 testing
Nonpharmacogenomic
Biomarkers
A measurable substance, structure or process in the
body or its products whose presence is indicative of
outcome or disease.
Occasional Cystatin-C
Epigenetics The natural occurrence of changes in gene expression
rather than changes in the DNA sequence
Not currently used/
research-based
Microbiome
(Pharmacomicrobiomics)
“The ecological community of commensal, symbiotic,
and pathogenic microorganisms” that inhabit our
bodies8; the microbiome composition contributes to
how individuals respond to medication leading to
suboptimal treatment
Not currently used/
research-based
Over 60 drugs have been identified
to have microbiome interactions
according to the Pharmaco
Microbiomics database (www.
pharmacomicrobiomics.com)
Demographics/lifestyle/
patient factors (weight,
age, race, environment,
diet, renal/liver function)
Common Dose adjustment
Drug selection
Abbreviations: INR, international normalized ratio; PT, prothrombin time.
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TABLE 2 Drugs with pharmacogenomic (PGx) guidance
Drug(s) or drug class PGx considerations PGx guideline
Other factors affecting drug response
that should be considered
Abacavir HLA-B CPIC, DPWG HIV genotype
Allopurinol HLA-B CPIC, ACR Renal status
Atazanavir UGT1A1 CPIC Drug interactions
HIV-1 genotype
Carbamazepine HLA-B CPIC, CPNDS Seizure type
Drug interactions
HLA-A Concomitant therapy
Celecoxib CYP2C9 CPICa Renal function
Liver function
Clopidogrel CYP2C19 CPIC, DPWG Disease history
Stent type
Bleeding risk
Codeine, oxycodone,
tramadol
CYP2D6 CPIC, CPNDS, DPWG Clinical factors
Social factors
Psychiatric comorbidities
CPIC, CPNDS, DPWG
Efavirenz CYP2B6 CPICa Drug interactions
HIV-1 genotype
History of psychiatric comorbidities
5-Fluorouracil DPYD CPIC, DPWG Myelosuppression
Inhaled anesthetics RYR1 CPIC Family history comorbidities
Interferon alpha INFL3 CPIC HCV type
Irinotecan UGT1A1 DPWG, RNPGx/GPCO-Unicancer Race
Ivacaftor
Lumacaftor and Tezacaftor
CFTR CPIC Liver status
Drug interactions
Mercaptopurine,
thioguanine,
azathioprine
TPMT CPIC, DPWG Myelosuppression
Liver function
Ondansetron CYP2D6 CPIC Liver status
Phenytoin CYP2C9
HLA
CPIC, DPWG Drug interactions
Concomitant therapy
Proton pump inhibitors CYP2C19 CPICa, DPWG Clinical factors
Concomitant therapy
Psychotropic agents
(eg, antidepressants,
antipsychotics)
CYP2C19
CYP2D6
CPIC, DPWG Clinical factors
Psychiatric comorbidities
Accurate diagnosis
Drug interactions
Family history of drug response
Social factors
Rasburicase G6PD CPIC Race
Pregnancy status
Food choices
Medication exposure
Simvastatin SLCO1B1 CPIC Concomitant therapy
Tacrolimus CYP3A5 CPIC, DPWG TDM
Tamoxifen CYP2D6 CPIC, DPWG Adherence
Voriconazole CYP2C19 CPIC TDM
Drug interactions
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drug-interactions, social/environmental factors (eg, smoking-induction
of CYP450 1A2), and resource (patient and community) availability.
Therapeutic drug monitoring is one objective method to help max-
imize the effectiveness and reduce adverse events for certain psychi-
atric medications (eg, clozapine, lithium, and nortriptyline).17
However, the evidence to support therapeutic drug monitoring is lim-
ited or absent for a majority of psychiatric medications. The use of
pharmacogenomic testing has begun to be applied to psychiatry in
clinical practice. Clinical studies assessing outcomes following
pharmacogenomic testing (eg, CYP2D6, CYP2C19) have been con-
ducted mostly in patients with major depressive disorder18 and indi-
cate the potential to reduce drug side effects, which can impact
adherence to treatment. However, the influence on efficacy or other
outcome measures has been mixed.18 There is less evidence demon-
strating benefit of pharmacogenomic testing in other psychiatric dis-
ease states, and there has been some concern that test results could
be misleading and potentially harm patients by avoiding certain medi-
cations on the premise of poorly correlated studies.19 There is signifi-
cant evidence linking the HLA-B*15:02 allele, which occurs
predominately in individuals of Asian ancestry, to risk for severe cuta-
neous reactions (eg, Stevens-Johnson syndrome and toxic epidermal
necrolysis) with carbamazepine, and testing is recommended in
genetically at-risk persons prior to carbamazepine use. Similar data
exist for phenytoin.
2.1.3 | Critical care PRN
The rapidly changing profile, acute organ dysfunction, and mul-
timorbidity alters drug pharmacokinetic profiles and pharmacody-
namic responses in critically ill patients. Using precision medicine to
tailor medication dosing to dynamic end organ function and apply
therapeutic drug monitoring using clinical response markers and drug
levels20 is common in critical care. Also, in adult and pediatric patients,
novel biomarkers such as procalcitonin, ferritin, C-reactive protein, cell
surface markers, interleukin-6, monocyte chemoattractant protein and
MAS, have been tested as tools to enhance severity of illness scores
(eg, APACHE) and disease models. Recently, distinct endophenotypes
of acute respiratory distress syndrome and sepsis have been identified
that are being used to enrich patient selection for targeted drug thera-
pies in clinical trials.21–23
Many of the drugs noted in Table 2 are commonly used in the crit-
ical care setting but whether acute illness alters gene expression and
the corresponding drug response is poorly studied. It is known that
certain genetic polymorphisms may introduce adverse drug reaction
TABLE 2 (Continued)
Drug(s) or drug class PGx considerations PGx guideline
Other factors affecting drug response
that should be considered
Warfarin CYP2C9
VKORC1
CYP4F2
CPIC Clinical factors
Social factors
Dietary considerations
Drug interactions
CPIC, CPNDS
Abbreviations: ACR, American College of Rheumatology3; CPIC, Clinical Pharmacogenetics Implementation Consortium4; CPNDS, Canadian
Pharmacogenomics Network for Drug Safety5; DPGW, Dutch Pharmacogenetic Working Group6; HCV, hepatitis C virus; HIV, human immunodeficiency
virus; RNPGx/GPCO Unicancer, French joint working group comprised of the National Pharmacogenetics Network [RNPGx] and the Group of Clinical
Onco-pharmacology (GPCO-Unicancer)7; TDM, therapeutic drug monitoring.
aGuideline in progress.
TABLE 3 Clinical examples of genotype-guided cancer chemotherapy
Somatic variant examples
Drug target Drug(s) Common malignancy
Echinoderm Microtubule Associated Protein-Like 4 and
Anaplastic Lymphoma Kinase (EML4-ALK)
Crizotinib, alectinib, ceritinib, brigatinib Nonsmall cell lung cancer
BCR-ABL Dasatinib, imatinib, nilotinib, bosutinib, ponatinib Chronic myelogenous leukemia
BRAF Vemurafenib, dabrafenib Melanoma
MEK Cobimetinib, trametinib Melanoma
Epidermal growth factor receptor (EGFR) Erlotinib, afatinib, gefitinib, osimertinib Nonsmall cell lung cancer
Human epidermal growth factor receptor 2 (HER2) Trastuzumab, lapatinib, pertuzumab,
Ado-trastuzumab emtansine
Breast cancer, gastric cancer
Janus kinase 2 (JAK2) Ruxolitinib Myelofibrosis
Rearranged during transfection (RET) Vandetanib, cabozantinib Medullary thyroid cancer
ROS1 Crizotinib, ceritinib Nonsmall cell lung cancer
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risks unique to the critical care environment such as sedative, analge-
sic, and antiepileptic response in traumatic brain injuries.24 However,
the role of genetic testing in the critically ill remains to be defined.
2.1.4 | Endocrine and metabolism PRN
Precision medicine in the realm of endocrinology is a growing area,
which is timely given the patient-centered and individualized care rec-
ommended by current clinical guidelines. Current treatment for type
1 diabetes lacks genetic testing precision; however, weight-based dos-
ing of insulin therapy is standard of care.25 Future precision medicine
tools that will afford clinicians the opportunity to detect patients who
may develop beta-cell loss resulting in hyperglycemia and those who
will experience disease complications will be an enormous advance-
ment in the treatment of diabetes.25
Genetic testing is useful in classifying single gene aberrations that
cause diabetes (approximately 1%-2% of diabetes), such as the HNF1A
variant in maturity-onset diabetes of the young and KCNJ11 and
ABCC8 variants in neonatal diabetes. In type 2 diabetes, genetic poly-
morphisms have been observed that influence glycemic response to
metformin (eg, SLC22A1, SLC47A1, and ATM).26 However, application
of these tests in the clinical setting is currently limited as the clinical
utility of these tests remains uncertain.
2.1.5 | Gastrointestinal/liver/nutrition PRN
Nutrition support provided through enteral and parenteral nutrition is
one of the most individualized, patient-specific therapies constituted
of macronutrients, micronutrients, and fluid required to sustain life in
those that cannot meet their needs orally. Pharmacists assist with cal-
culating caloric provisions based on patient-specific factors or indirect
calorimetry measurements and detect nutrient deficiencies through
laboratory monitoring and clinical evaluation. Therapy is continually
altered as the patient's clinical status changes and tailored to replete
deficiencies or maintain adequate nutritional health.
Treatment for gastrointestinal diseases, such as inflammatory
bowel disease (IBD), hepatitis C (HCV), and gastroesophageal reflux
disease, is often guided by renal/hepatic function, concurrent and
prior medication use, adherence, present symptoms, and genotype.
Presently, for IBD, monitoring troughs of certain tumor necrosis factor
(TNF)-alpha inhibitors to predict the likelihood of antidrug antibodies
is useful to detect efficacy and minimize toxicity. Concomitant ther-
apy with immunomodulators lowers TNF-alpha induced immunoge-
nicity, but causes hematopoietic toxicity and warrants genotype or
enzyme testing of thiopurine S-methyltransferase (TPMT) and nudix
hydrolase (NUDT15) to determine toxicity risk with thiopurines use.27
Similarly, precision medicine is applied in treating HCV (Table 2).
The emergence of direct activating antivirals has boosted cure rates
and improved the proportion of patients treated, but requires assess-
ment of prior treatment history, disease severity, contraindications
with concomitant medications, existing comorbidities (human immu-
nodeficiency virus [HIV] or hepatitis B), adherence, HCV genotype,
and viral load prior to initiation. Testing for resistance of certain
proteins (eg, NS5A) is warranted in specific situations (eg, initiation of
certain regimens, treatment failure) and may further guide treatment
selection and duration.28 Finally, precision medicine can be applied in
patients treated with proton pump inhibitors (PPIs) for acid-related
disorder. PPIs are metabolized by CYP2C19 and CYP3A4, and
CYP2C19 poor metabolizers may be at increased risk for adverse
effects while rapid and ultrarapid metabolizers are at risk for treat-
ment failure, with the strongest data related to Helicobacter pylori
eradication. Thus, CYP2C19 genotyping may be useful in personalizing
PPI dosing, though it is not broadly utilized in practice likely due to a
lack of knowledge of the association and how to use genotype to
guide prescribing. However, evidence review and guidelines for the
use of CYP2C19 testing for PPI therapy are forthcoming by CPIC.29
2.1.6 | Hematology/oncology PRN
Precision medicine has revolutionized the field of oncology and led to
advances in both the development and use of therapies to target
somatic (tumor) genetic alterations as well as to improve toxicity and
efficacy outcomes by analyzing germline pharmacogenomic alter-
ations. Integrating the knowledge of germline and somatic alterations
into clinical practice is now standard of care at many centers and pro-
vides an opportunity for pharmacists practicing in oncology to opti-
mize treatment and supportive care recommendations.30
The increased understanding of cancer biology in conjunction with
advances in molecular technology has helped identify numerous com-
mon drivers of oncogenesis. As molecular targets have been identi-
fied, oncology drug development has produced numerous successful
targeted agents with thousands more currently in the development
pipeline.31 Genetic tumor testing is performed to provide both prog-
nostic and predictive information to guide further patient care. For
example, common predictive alterations include EGFR activating
variants in nonsmall cell lung cancer that are associated with a
response to EGFR inhibitors such as erlotinib, gefitinib, afatinib and
osimertinib, and BRAF V600 activating variants in melanoma that are
associated with response to inhibitors of BRAF (vemurafenib and
dabrafenib) and MEK (cobimetinib and trametinib).32 Numerous other
examples of predictive genetic alterations in oncology exist and
selected examples are presented in Table 2. Genetic testing of tumors
is now part of standard practice to help determine disease risk classifi-
cation in myeloid malignancies, identify standard of care targeted
therapy options as discussed above, or identify treatment options for
patients who are diagnosed with less common malignancies such as
Merkel cell carcinoma or certain subtypes of sarcoma. Tumor genetic
testing frequently involves not just assessing the clinical importance
of one or two genes but can include consideration of the interplay of
numerous genes that may be altered in a tumor. Numerous databases
are available to assist with clinically interpreting genetic variants from
these reports.30 Molecular tumor boards (MTBs), multidisciplinary
groups of oncologists, pathologists, medical geneticists, basic scien-
tists, pharmacists, and other interprofessional care team members,
synthesize the literature for the individual patient and his or her
unique characteristics to ultimately produce a treatment plan.30 Given
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a pharmacist's background in cancer biology and pharmacology, the
profession is well positioned to provide valuable recommendations at
MTB meetings, and some interdisciplinary MTBs have been developed
and are under the leadership of pharmacists.30,33
Germline pharmacogenomic testing is also used in standard oncol-
ogy practice to help minimize toxicity while maximizing efficacy of
cytotoxic chemotherapy agents. The importance of drug and dose
selection in oncology is underscored by the narrow therapeutic index
of many oncology agents. Examples of germline pharmacogenomic
testing in oncology include TPMT and NUDT15 testing for patients
receiving mercaptopurine and thioguanine, commonly used in acute
lymphocytic leukemia regimens, and DPYD testing for patients receiv-
ing fluorouracil or capecitabine, commonly used in colorectal cancers
as well as other solid tumors.34–36 Other examples of relevant
germline pharmacogenomic genes associated with drugs (eg, tamoxi-
fen, allopurinol, and rasburicase) commonly used in the oncology pop-
ulation are listed in Table 2.
2.1.7 | HIV PRN
The goals of precision medicine and antiretroviral (ARV) therapy are
multifactorial and are both drug- and disease-related. Drug-related
factors include optimization of regimen efficacy, minimization of drug
toxicity, and prevention of ARV resistance. Disease-related goals
include reducing overall morbidity and mortality by optimizing immu-
nologic recovery and virologic suppression. Interpatient variability
presents unique challenges for people living with HIV (PLWH). Con-
tributing factors include comorbid conditions, opportunistic infections,
drug-drug (including complementary alternative medicines) and/or
drug-disease interactions, medication adherence, ARV pharmacokinet-
ics/pharmacodynamics (PK/PD), pharmacogenomics, viral genetics,
age, gender, and ethnicity. Many of these factors have helped inform
actionable practices and implementation of precision medicine into
the clinical care of PLWH, while others are still being investigated.
The CPIC and current ARV guidelines by the US Department of
Health and Human Services provide several recommendations for
individualization of therapy.37 In the Food and Drug Administration
(FDA) boxed warning for abacavir, screening for the HLA-B*57:01
allele is recommended prior to starting abacavir-containing regimens,
as this approach has been found to significantly decrease the risk of a
hypersensitivity reaction. Prior to initiating ARVs or when assessing
the presence of ARV-associated resistant variants during treatment
failure, HIV viral genotyping and drug specific assays (eg, HIV-1 tro-
pism) are recommended to tailor and optimize therapy. When con-
structing a regimen, coinfection with hepatitis B must be considered
to ensure inclusion of a tenofovir and emtricitabine/lamivudine back-
bone. Individualizing therapy is particularly important in the current
population of PLWH as more than 50% are over the age of 50 and
have multiple comorbid conditions (eg, hepatitis C, dyslipidemia,
coagulopathy) where drug-drug interactions and overlapping toxicities
must be managed.38 Ongoing investigations to further support preci-
sion medicine such as therapeutic drug monitoring, optimal PK/PD
indices of ARVs, gender differences in tolerability, ARV tissue
distribution for the prevention of HIV, novel drug delivery systems,
and pharmacogenomic variants are still underway. Other applications
of pharmacogenomics to ARV include UGT1A1-guided atazanavir
use39 and CYP2B6-guided efavirenz dosing,40 though these are not
yet widely used in clinical practice, likely because these agents have
fallen out of favor in the United States due to the availability of better
tolerated medications, and testing is not readily available outside of
the United States.
2.1.8 | Immunology/transplantation PRN
Although guidelines exist, what constitutes standard of care manage-
ment in solid organ transplantation varies widely, particularly with the
application of precision medicine. Precision medicine is utilized in all
phases of transplantation (pretransplant, peri-operatively, and post-
transplant) by a multidisciplinary team which includes physicians,
pharmacists, pathologists, immunologists, nurses, social workers,
and dieticians. To determine if a patient has low or high immuno-
logic risk, factors including race/ethnicity, class I and class II
human leukocyte antigen (HLA) donor mismatch, age, calculated
panel reactive antibody, ABO blood type, and donor characteristics
as quantified by the Kidney Donor Profile Index should be consid-
ered while genomics are utilized to determine the type and expo-
sure of immunosuppression used for each specific transplant
patient.
The precision medicine needs of a transplant recipient change
over time with the continuing goal of balancing adequate immunosup-
pression to prevent allograft injury with the risks of infection, malig-
nancy, and adverse side effects. Tacrolimus is the cornerstone of
modern immunosuppressive therapy yet there are significant chal-
lenges in defining what constitutes “adequate” levels for each individ-
ual patient. Perhaps the most clinically relevant example of
pharmacogenomics in solid organ transplantation is CYP3A5 testing to
guide tacrolimus (TAC) dosing (Table 2). CYP3A5normal and interme-
diate metabolizers (“expressers”) are expected to require a dose that is
1.5-2 times higher than standard dosing to achieve therapeutic plasma
concentrations.38 Currently, in most medical centers, CYP3A5
genotyping to guide TAC dosing is not standard practice and dosing is
guided by therapeutic drug monitoring (TDM). In contrast to TDM,
which must be done after a drug is started, genetic testing can be
done a priori to guide initial TAC dosing, thus potentially reducing the
time to achieve therapeutic drug levels. Testing may be of particular
benefit in centers that serve a racially diverse population given the
higher frequency of functional CYP3A5 alleles in persons of African
ancestry. African American patients are more likely to be CYP3A5
normal and intermediate metabolizers; hence, higher doses are rec-
ommended in this patient population.41
2.1.9 | Infectious diseases PRN
Infectious diseases clinicians routinely use PK and PD principles to
guide treatment decisions. It is a common practice at hospitals for
pharmacists to streamline antimicrobial selection based on infection
294 CAUDLE ET AL.
site, microbiology culture, and sensitivity reports and to adjust the
dosing of antimicrobials based on infection site and renal function.
The Infectious Diseases Society of America and the Society for
Healthcare Epidemiology of America guidelines for implementing an
antimicrobial stewardship program recommend antimicrobial dosing
optimization and microbiology diagnostics integration as key strate-
gies to improve patient outcomes while halting antimicrobial resis-
tance, decreasing adverse effects, and controlling costs.42 The
guidelines specifically recommend that hospitals implement pharma-
cokinetic monitoring and adjustment programs for aminoglycosides
and vancomycin, which has become a standard of practice for
hospital-based pharmacists.42 The guidelines also recommend that
antimicrobial stewardship programs advocate for alternative dosing
strategies for broad-spectrum beta-lactams, which is becoming a com-
mon hospital practice for piperacillin/tazobactam, ceftazidime,
cefepime, and meropenem.42 In addition, the guidelines recommend
development of stratified antibiograms with selective and cascade
reporting of antibiotics and the use of rapid diagnostic testing (eg,
MALDI-TOF, PNA FISH ± MCA, PCR, serology, etc.) and procalcitonin
to optimize antimicrobial use, which is becoming increasingly popular
in academic medical centers.42 Many molecular rapid diagnostic test-
ing are capable of detecting genes associated with antimicrobial resis-
tance and the FISH/MCA system is capable of revealing phenotypic
resistance patterns.43 Although guidelines exist for the use of
CYP2C19 genotype to guide voriconazole use,44 the use of pharmaco-
genomics to guide antimicrobial drug selection and dosing is rarely
used at present. This may be reflective of a lack of knowledge about
genetic associations with voriconazole disposition or about the avail-
ability of genetic testing to optimize voriconazole dosing. Alterna-
tively, establishing processes by which genotype information is
available at the point of prescribing is a challenge, yet is ideal for drugs
like voriconazole, especially for life-threatening invasive fungal infec-
tions where it is critical to efficiently attain therapeutic drug levels.
The expected increase in preemptive pharmacogenomic testing
models in the future will help to address this challenge.
2.1.10 | Nephrology PRN
Pharmacists have long been at the forefront of precision medicine,
specializing in tailoring medication doses for patients with kidney dis-
ease (Table 1) and for those receiving dialysis. More recently,
advances in molecular genetics have informed development of novel
biomarkers associated with estimated glomerular filtration rate
(eGFR), end stage renal disease, acute kidney injury (AKI), and chronic
kidney disease progression. Also, molecular genetics has identified
genes and variants associated with kidney disease that can provide
opportunities for targeted therapies.45
Urinary biomarkers for early detection of AKI have always been
an area of great interest and study. Furthermore, attention has been
paid to more fully characterizing phenotypes of drug-induced AKI to
better establish causality. The International Serious Adverse Events
Consortium recently convened a panel (including pharmacists) which
proposed four phenotypes of drug-induced kidney disease based on
clinical presentation: AKI, glomerular disorder, tubular disorder, and
nephrolithiasis/crystalluria. This framework is valuable for evaluating
drug toxicity and patients at risk for drug-induced AKI.46
Several new serum and urinary biomarkers suitable for use as an
adjunct or alternative to creatinine for kidney assessment have been
identified. In 2018, FDA's Predictive Safety Testing Consortium
approved the use of six urinary biomarkers to aid in the detection of
AKI in early phase clinical trials including clusterin, cystatin-C, kidney
injury molecule-1, N-acetyl-beta-D-gluconsaminidase, neutrophil
gelatinase-associated lipopcalin, and osteopontin.47 Less invasive
methods, including tracking transdermal fluorescent compounds, will
enable clinicians to more accurately estimate GFR and identify early
changes in kidney function.48 Additionally, the use of electronic health
records and predictive analytics when combined with AKI biomarkers
could be used to flag patients in real time.49
2.1.11 | Pain and palliative care PRN
Assessing (and reassessing) each patient's risks and benefits with
respect to symptom directed therapy is essential to maintain efficacy
with minimal toxicity. The basics of symptom management include
understanding the extent and timeline of the disease or injury, the
magnitude of the illness, expected relief (or not), symptom severity
and interference, and functional limitations. Pain-specific assessments
should also include pain sensitivity, central sensitization characteris-
tics, a complete biopsychosocial assessment, and risks of dependence,
abuse, respiratory depression, and diversion.50 Assessing comorbid
conditions and concomitant medications are vital to estimating the
risk-to-benefit of drug therapy, particularly opioids. Safe and effective
management of pain and associated symptoms (eg, anxiety/
depression, fatigue) requires in-depth patient assessment and individ-
ualized treatment approaches.
Precision medicine for management of pain, whether acute or
chronic, may include the application of pharmacogenomic testing. A
recent comprehensive review of opioid pharmacogenomics and clini-
cal pain management describes genetic associations with opioid effec-
tiveness and safety.51 The most evidence exists for the CYP2D6
genotype related to codeine and tramadol response (Table 2). Of par-
ticular concern is the risk for serious adverse effects including respira-
tory depression and even death with tramadol or codeine use in
CYP2D6 ultra-rapid metabolizers. Poor metabolizers, on the other
hand, may not attain pain relief from codeine or tramadol. Notably, a
number of drugs inhibit the CYP2D6 enzyme and may phenotypically
convert patients with a normal metabolizer genotype to the interme-
diate or poor metabolizer phenotype. Other opioids such as oxyco-
done and hydrocodone are metabolized by CYP2D6 but limited data
exist on how to use this information clinically.51 Other potential appli-
cations of pharmacogenomic data for pain management include
CYP2D6 and CYP2C19 testing for tricyclic antidepressants selection
and dosing,52,53 and CYP2C9 testing for select NSAIDs54 (Table 2).
CAUDLE ET AL. 295
2.1.12 | Perioperative care PRN
There are many examples of practices used to guide patient care
throughout the continuum of the perioperative period. Preadmission
testing allows for identification of patients with specific intraoperative
risks (eg, difficult airway, intraoperative or postoperative ischemic
events, personal or family history of malignant hyperthermia [MH],
postoperative nausea/vomiting [PONV], etc.) for whom early recogni-
tion and therapy implementation or adjustment can minimize or miti-
gate potential complications. For example, in patients with a history of
hypertension, guidelines recommend establishing target systolic blood
pressure (SBP) or mean arterial pressure (MAP) goals based on the
patient's resting blood pressure (BP) prior to surgery rather than using
a standardized approach.55 This patient-specific baseline is then used
as the target ±10% SBP or MAP throughout surgery to decrease risk
of ischemic injury (particularly neurologic or renal). A recent clinical
trial found significantly less neurologic and renal injury when patients
were maintained at their target BP rather than at a standard BP.56
Precision medicine is also seen in the implementation of enhanced
recovery pathways, including continuous hemodynamic and oxygen
delivery monitoring to mitigate organ ischemia through goal-directed
fluid therapy and/or the addition of inotropes or vasopressors while
minimizing fluid overload.57
Precision medicine is incorporated in the perioperative arena for
three specific scenarios: prevention of MH, PONV, and surgical site
infections. Preventing the life-threatening complication of MH in
patients with a personal or family history of MH now incorporates not
only clinical history and a muscle biopsy with an in vitro contracture
test (IVCT) but also DNA testing (Table 2). Current guidelines recom-
mend at risk patients undergo DNA screening first and only proceed
to the biopsy and IVCT if no MH variant is detected.58 PONV occurs
in 30%-50% of all patients undergoing surgery. Identifying patients at
risk using validated scoring systems facilitates the development of a
patient- and procedure-specific antiemetic regimen59 and the CYP2D6
genotype can affect ondansetron efficacy (Table 2). Third, the selec-
tion and dosing of antimicrobial surgical prophylaxis based on patient-
specific factors (eg, allergies and weight) and surgery-specific factors
including type, location, and duration is employed to decrease the risk
for surgical site infections.60
2.1.13 | Pulmonary PRN
There are several disorders in pulmonary medicine for which precision
medicine is practiced today, including but not limited to cystic fibrosis
(CF), interstitial lung disease, asthma, alveolar proteinosis, alpha-1
antitrypsin deficiency-associated emphysema, primary and secondary
immunodeficiencies, and others. Prior to 2011, therapy for CF was
limited to supportive care; however, with the approval of ivacaftor
(Table 2), the first CFTR potentiator that targets specific CFTR defects
(eg, G551D), CF patients with these inherited variants have seen
greater improvement in lung function.61 Since the introduction of
ivacaftor, other CFTR modulators have been introduced targeting
other CFTR defects resulting in improved outcomes for this patient
population.61 The FDA has recently expanded approval of these mod-
ulators to include rare CFTR variants based on in vitro data, which will
expand access to these targeted therapies for smaller subsets of
patients who may benefit.
Precision medicine has provided substantial advances in the diag-
nosis and management of asthma over the past decade. Asthma is
now recognized as a substantially heterogeneous disease with wide
variation in response to conventional therapies.62 Multiple investiga-
tors have studied several therapies for specific phenotypes of severe
asthma, particularly those with detectible elevations in eosinophil
levels in the sputum, including those targeted at IgE, interleukin (IL) 5
receptor alpha (IL-5Ra), IL-4Ra, and IL-13. These therapies, including
omalizumab (anti-IgE), dupilumab (anti-IL4), reslizumab and
mepolizumab (anti-IL5), and lebrikizumab (anti-IL13) are intended for
patients with severe asthma symptoms that are uncontrolled on maxi-
mal medical therapy or as a means to minimize high-dose corticoste-
roid exposure.63 Importantly, these therapies are only effective in the
asthmatic patient with the respective phenotypic polymorphisms as
described above. Thus, precision medicine testing, diagnostic, and
treatment approaches are critical to best caring for patients with the
most severe manifestations of asthma.
2.2 | Generalist/special population specialties
2.2.1 | Pediatrics PRN
There are unique challenges with the use of precision medicine in
pediatrics. The pediatric patient population includes neonates
weighing 500 g to adolescents weighing 300 kg, and within this popu-
lation there exists many developmental physiologic differences
resulting in a widely heterogeneous population.64 Children are a vul-
nerable population and dosing recommendations are often extrapo-
lated from existing adult data. Despite legislation to promote pediatric
drug development, only two-thirds of completed pediatric trials have
resulted in pediatric labeling.65 Additionally, dosage formulation
manipulation for extemporaneous enteral formulations and drug dilu-
tions for intravenous products are daily occurrences to create formu-
lations necessary for drug delivery to this patient population,
commonly without validated formulation or supporting data.64
Despite these challenges, there have been advances made towards
precision medicine use in pediatrics.
Therapeutic drug monitoring (TDM) is an effective approach for
precision medicine in pediatrics, including neonates and infants, spe-
cifically for medications with a narrow therapeutic range.65 TDM is
most commonly used for vancomycin, aminoglycosides, digoxin, caf-
feine, and anticonvulsants.66 Using knowledge of developmental phar-
macological differences across the age continuum and
pharmacokinetic/pharmacodynamic drug information from adult data,
a pediatric pharmacist can make dosing recommendations and then
use TDM to assess the efficacy and/or safety of the dose. In the
future, incorporating TDM into the drug development phase rather
than relying on fixed-dose or strictly weight-based pediatric trials may
facilitate better pediatric indication labeling.65 This may result in
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appropriate evidence-based medication selection and improved initial
dosing recommendations for efficacy and safety with a reduced need
for TDM.
Pharmacogenomic testing in pediatrics is evolving and expanding.
Areas that are currently being studied include pain management,
immunosuppression, childhood cancer, mental health, asthma, neurol-
ogy, and cystic fibrosis. In pain management, CYP2D6 genotyping has
been used to identify polymorphisms affecting codeine metabolism
and increasing risk for toxicity or poor analgesic response (Table 2).
Based on reports of toxicity including death with codeine use in chil-
dren with the CYP2D6 ultra-rapid metabolizer phenotype, a boxed
warning was added to the codeine labeling warning against codeine
use in patients less than 18 years of age.67 Despite this, codeine
remains the most commonly prescribed opioid in children less than
18 years of age highlighting the potential role for CYP2D6 testing
when prescribing codeine.67 The use of precision medicine in immu-
nosuppression, cancer, mental health, asthma, and cystic fibrosis are
discussed in the respective sections of this paper.
Appreciating the effects of ontogeny during the drug development
phase may also result in improved drug dosing, thereby increasing
safety and decreasing toxicity profiles of medications given to pediat-
ric patients.68
2.2.2 | Women's health PRN
Sex-related differences impact drug PKs and PDs and thus drug selec-
tion and dose. For example, antithrombotic agents (eg, aspirin,
GPIIbIIIa inhibitors) that are used to treat cardiovascular disease have
different pharmacokinetics in women, which may increase adverse
effects and require dosage adjustments.69 Also, the FDA recommends
that an initial dose for women of zolpidem be only 5 mg because
clearance of the drug is lower in women as compared with men.
Women also have a higher risk of drug-induced long QT syndrome
with antiarrhythmics (eg, quinidine, procainamide and disopyramide,
sotalol and amiodarone)70 and antipsychotic drugs (eg, thioridazine,
haloperidol, risperidone, olanzapine, and ziprasidone).71,72 In the treat-
ment of depression, whereas men respond better to tricyclic antide-
pressants, women respond better to selective serotonin reuptake
inhibitors.73,74 Furthermore, the impact of oral contraceptives on
pharmacokinetics and pharmacodynamics needs to be considered.
Among other risks from oral contraceptives, women using these prod-
ucts may be at increased risk of venous thromboembolism. Patients
with thrombophilias such as Factor V Leiden or prothrombin variant
are predisposed to a particularly high risk of clotting, and safer alter-
native contraceptive measures should be considered. We have
included a limited number of examples here; however, it is important
to recognize that there are a broad range of sex- and gender-based
medication issues that need to be taken into account in precision
medicine.
Clinical pharmacists incorporate knowledge of pregnancy-induced
changes in pharmacokinetics (eg, changes in renal filtration, renal drug
transport, drug metabolism and binding) into practice to optimize effi-
cacy at the same time as considering maternal, fetal, and neonatal
safety in medication selection and dosage. For example, nifedipine, a
CYP3A substrate, is known to have a higher apparent oral clearance
and shorter half-life during pregnancy suggesting that higher doses
and a shorter dosing interval should be considered. Another example
is when using metoprolol for rate control of supraventricular tachycar-
dias, a much higher dosage is needed during pregnancy. This dosage
escalation not only reflects the increased elimination of metoprolol,
but also the gestational age-dependent increase in heart rate that
occurs in normal pregnancy. As an alternative to metoprolol, atenolol
should be considered because it avoids the induction seen in the
metabolism of metoprolol and provides a more predictable pharmaco-
kinetic profile during pregnancy. Unfortunately, at many institutions,
pregnant women are receiving exactly the same medications and
doses as they received prior to pregnancy resulting in unnecessary
subtherapeutic concentrations or toxic effects. Even more concerning
is when all medications are discontinued because the woman
becomes pregnant leading to a wide range of complications which are
far more dangerous to the pregnant woman, fetus, and neonate than
the continuation of those medications during pregnancy. Thus, preci-
sion medicine during pregnancy must include a risk-benefit analysis of
the medications as well as risks of untreated conditions during preg-
nancy. A detailed review of the pregnancy-induced changes in drug
metabolism, renal filtration, and active drug transport, which are being
used by pharmacists to modify drug therapy during pregnancy can be
found elsewhere.75
2.2.3 | Ambulatory care PRN
Given the long-term patient provider relationship, ambulatory care
pharmacists are well positioned to broadly apply precision medicine
approaches described in previous sections to their patients as part of
existing comprehensive medication management services. Common
precision medicine approaches already utilized by ambulatory care
pharmacists include statin selection based on individual cardiovascular
risk, warfarin dosing individualized to vitamin K intake, and medication
optimization to patient-specific socioeconomic and functional status
changes.
Applying patient-specific data and pharmacogenomics prior to the
use of many common medications such as anticoagulants and antide-
pressants has been shown to improve efficacy, safety, and/or therapeu-
tic outcomes in targeted patient populations.76,77 Pharmacogenomic
data can also be beneficial when used within an existing treatment regi-
men to guide medication dosage/selection of alternative treatment reg-
imens in at-risk patients (eg, those experiencing adverse effects or lack
of response to proven therapies). Ambulatory care pharmacists are
increasingly applying the principles of precision medicine, particularly
pharmacogenomics, across a range of practice models including
pharmacist-led chronic disease state or medication management ser-
vices, consultation services to help interpret pharmacogenomic test
results, and standalone pharmacist-led pharmacogenomics clinics.78,79
When genomic data are available, ambulatory care pharmacists should
utilize these data to help guide medication selection (ie, statin selection
in familial hypercholesterolemia, chemoprevention regimen in BRCA
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gene carriers). As direct-to-consumer genetic testing expands, ambula-
tory care pharmacists will also increasingly be called upon from inside
and outside the profession to educate patients on the merits of
pharmacogenomic and direct-to-consumer genetic testing and offer
guidance to providers on applying direct-to-consumer genetic test
results to clinical decision making.80,81
2.3 | Drug development and outcomes specialties
2.3.1 | Pharmaceutical industry
Competition throughout the pharmaceutical industry in addition to
government initiatives and acceleration of the drug approval process
has fostered development of precision medicines that have changed
the treatment landscape for many diseases. New products have been
designed with a therapeutic advantage or less risk of toxicity to the
standard of care for a condition (eg, ledipasvir/sofosbuvir for hepatitis
C) while others are the first treatments for special populations (eg,
nusinersen for spinal muscular atrophy). Drug discovery targeted at
specific genetic features (biomarkers) has transformed the treatment
of many types of cancers, as discussed in the oncology section. Prod-
ucts with selective targets may have an associated companion diag-
nostic test to confirm presence or expression of the biomarker prior
to treatment.82 Many of the new products are classified as specialty
medications and have higher medication costs per treatment to coun-
terbalance use in a more specific population.
Gene therapy is an innovative technology developed to treat or
cure disease by incorporating new genes, replacing mutant genes, or
silencing mutated genes.83 Two gene therapies are FDA-approved for
the treatment of specific types of cancer in which a custom product is
created for each patient by extracting the patient's own T-cells and
integrating a new gene.84,85 Following genetic modification, the T-
cells express a receptor that can recognize and attack malignant cells.
The first viral vector gene therapy was FDA-approved to replace a
mutated gene associated with vision loss and blindness with a normal
gene by intraocular injection.86 Gene therapies with the ability to
silence mutated genes are still under development. The recent
approval of the antisense oligonucleotide nusinersen for the treat-
ment of spinal muscular atrophy (SMA) is a milestone for both SMA
treatment and the clinical availability of oligonucleotide
technologies.87
As the concept of precision medicine continues to evolve, designs
of clinical trials are also advancing.88 Drug development in oncology
has been on the forefront of implementing new clinical trial designs
due to the discovery of specific biomarkers, availability of expedited
review from the regulatory bodies, and better return on investment
compared with other disease states.89 For example, early phase drug
development in oncology frequently employs umbrella and basket trial
designs.90 Basket trial design involves screening patients with differ-
ent oncologic diseases or histological features for a specific drug tar-
get before enrolling only target-positive patients into a trial.91
Umbrella trial design focuses on screening multiple patients for vari-
ous biomarkers and then stratifying all screened patients into drug
treatment arms based on the presence of specific biomarkers. Such
designs result in smaller patient enrollments per study drug. Smaller
clinical trials will become more prevalent compared with the tradi-
tional study designs with subgroup analyses.88 However, several
drawbacks and roadblocks limit widespread implementation of the
new trial designs. Companion diagnostics are necessary for identifying
and enrolling patients with the right targets into clinical trials, but only
a small portion of agents with companion diagnostics reach late-stage
drug development.89,90 New trial designs are also at a disadvantage
due to small numbers of enrolled patients, insufficient safety data
from small sample sizes, lack of outcomes data in negative-target
patients, and unclear fit into the current regulatory guidelines.90
Nonetheless, different players in the health care industry ranging from
pharmaceutical industry to health care providers will need to create
systems and improve these developing trial designs to allow new
targeted agents to reach the right patient at the right time, which is at
the core of precision medicine.
2.3.2 | Health outcomes
Value can be defined in various ways. Economic value is what
resources, time, money, or lost opportunities an individual is willing to
spend to receive a good or service. In health care, value is defined as
an outcome—clinical, patient satisfaction, quality of life—compared
with a cost and is usually determined through cost-effectiveness and
cost-utility analyses. Value must be evident for universal acceptance
of health care services and recommendations by providers, patients,
and payers. When applied, precision medicine may lead to selection of
efficacious medications, avoidance of subtherapeutic drugs, and
reduction of adverse events, adverse drug interactions, and emer-
gency room visits. However, data showing improved clinical and eco-
nomic outcomes with genotype-guided therapy are currently limited.
Additional data are expected from on-going trials.
Demonstrating value in precision medicine presents multiple chal-
lenges. Value is determined on a population basis; however, precision
medicine affects subsets of patients and even individuals. Additionally,
testing costs significantly influence the value of personalized treat-
ments and may not always be cost-effective.92 The limited data from
pragmatic studies with long-term outcomes further complicates value
analysis.93 Ongoing trials, adoption of electronic health records (EHR),
and the ability to generate “big data” may address some barriers.
However, this may result in changes to outcome assessment, require
new models to assign value, and even generate new definitions of
value. Value may exist in hope, reduced uncertainty, potential to
improve or prolong life, or scientific knowledge gains.94
There are mixed opinions on whether data from randomized con-
trolled trials, the evidence gold standard, are necessary to support
adoption of genotype-guided therapy in practice. Some argue that, as
with everything in health care, precision medicine must demonstrate
the value of the care provided. However, demonstrating positive clini-
cal outcomes and cost effectiveness with each example of genotype-
guided therapy will likely be a slow process, especially if a randomized
controlled trial is required for each example. Others believe that
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genotype is yet another factor to assist with drug selection and dos-
ing, much like serum creatinine. Indeed, serum creatinine is routinely
measured prior to drug prescribing, yet there are no randomized con-
trolled trials demonstrating its benefit. Regardless, the emergence of
additional data and ongoing real-world experiences will continue to
help define the value of precision medicine.
3 | CONCLUSION
Pharmacists have long utilized individual patient factors and consider-
ations for medication optimization. As medication experts committed
to comprehensive medication management, they are well positioned
to ensure each patient receives the right dose of the right medicine at
the right time. In today's age of “precision medicine,” clinical pharmacy
practice has grown to incorporate genotype and gene expression data
along with more traditional patient specific characteristics to better
tailor drug therapy. As pharmacists generations ago learned to
embrace and leverage therapeutic drug monitoring to improve patient
care and outcomes, today's clinical pharmacy practitioners are best
positioned to apply genomic advances to inform selection of medica-
tion therapy.
Evidence-based clinical guidelines are available to direct medica-
tion use in the presence of pharmacogenomics information. As
supporting evidence for clinical implementation of pharmacogenomics
is generated and pharmacogenomic test results become increasingly
available, pharmacists should prepare to lead the adoption of this
information into routine patient care as they have traditionally done
for therapeutic drug monitoring. Barriers to successful implementation
of pharmacogenomics programs, as well as potential solutions, have
been previously described in detail.95–98 A key challenge is incorporat-
ing genetic data appropriately with other clinical factors to optimize
therapy and building clinical decision support to facilitate this in prac-
tice. We also need to move past reactive, single gene tests and move
towards array-based, preemptive pharmacogenomic testing, as this is
a more cost-effective approach. Supporting such a program, however,
requires robust informatics support. There are a number of other
urgent professional needs in this expanding area to support the devel-
opment and sustainability of pharmacy practice models that appropri-
ately incorporate pharmacist expertise, including developing avenues
for consistent reimbursement of pharmacist cognitive services, inte-
gration of genomic information into existing pharmacy practice
models, consistent documentation and access to this information, and
large-scale pharmacist and clinician educational efforts. Education is
critical to ensure that clinicians are aware of clinically significant
pharmacogenomic associations and the availability of testing. The abil-
ity as a profession to meet these needs will influence whether phar-
macists are able to scale precision medicine services into more
widespread and sustainable clinical implementation models.
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